Newsroom | 19109 results

INDIANAPOLIS--(BUSINESS WIRE)--Governor Braun visited Ossium Health's production facility, celebrating how the company embodies Indiana's reputation as a life sciences powerhouse....

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a developer of the leading AI foundation model for tumor and immune biology, today announced that 13 abstracts have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, held from April 17 - 22, at the San Diego Convention Center in San Diego, CA. BostonGene will be exhibiting at booth #4613. BostonGene will demonstrate how its leading AI foundation model for tumor and immune biology is redefining...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business is launching Signals BioDesignTM, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update on a recent decision issued by the United States District Court in the District of Delaware regarding Natera’s litigation with ArcherDx and Invitae. In a decision issued on April 6, 2026, the Court ordered an ongoing royalty to Natera of 30% on post-injunction revenues from infringing MRD-related product sales that fall within the exceptions to the injun...

OTTAWA, Ontario--(BUSINESS WIRE)--Virica Biotech (« Virica »), entreprise spécialisée dans les activateurs cellulaires et plus particulièrement les sensibilisateurs viraux (VSE™) pour la production de vecteurs viraux, a annoncé aujourd'hui qu'elle bénéficie de services de conseil et d'un financement du Programme d'aide à la recherche industrielle du Conseil national de recherches du Canada (PARI CNRC), dans le cadre du Programme de coinnovation Canada-Japon, lui permettant de collaborer avec FU...

OTTAWA, Ontario--(BUSINESS WIRE)--Virica Biotech („Virica“), ein auf Zellverstärker spezialisiertes Unternehmen, das Viral Sensitizers (VSE™) für die Herstellung viraler Vektoren entwickelt, gab heute bekannt, dass es im Rahmen des Canada–Japan Corporate Co-Innovation Program für eine Zusammenarbeit mit FUJIFILM Biosciences Beratungsleistungen und Finanzmittel vom Industrial Research Assistance Program (NRC IRAP) des National Research Council of Canada erhält. Die Zusammenarbeit konzentriert si...

OTTAWA, Ontario--(BUSINESS WIRE)--Virica Biotech ("Virica"), een bedrijf dat zich specialiseert in virale sensibilisatoren (VSE™) voor de productie van virale vectoren, heeft vandaag aangekondigd dat het adviesdiensten en financiering ontvangt van het Industrial Research Assistance Program (NRC IRAP) van de National Research Council of Canada. Dit vindt plaats in het kader van het Canada–Japan Corporate Co-Innovation Program voor een samenwerking met FUJIFILM Biosciences. Deze bekendmaking is o...

OTTAWA, Ontario--(BUSINESS WIRE)--Virica Biotech («Virica»), una empresa dedicada al desarrollo de potenciadores celulares especializada en sensibilizadores virales (VSE™) para la fabricación de vectores virales, ha anunciado hoy que recibirá servicios de asesoramiento y financiación del National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), en el marco del Canada-Japan Corporate Co-Innovation Program, para una colaboración con FUJIFILM Biosciences. El comunicado...

OTTAWA, Ontario--(BUSINESS WIRE)--Virica Biotech (“Virica”), azienda produttrice di potenziatori cellulari, specializzata in Viral Sensitizers (VSE™) per la produzione di vettori virali, oggi ha annunciato che riceverà servizi di consulenza e finanziamento dal National Research Council of Canada Industrial Research Assistance Program (NRC IRAP, Programma di assistenza alla ricerca industriale del Consiglio nazionale del Canada per la ricerca), nell'ambito del Canada–Japan Corporate Co-Innovatio...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 69,140 shares of the Company’s common stock to four new employees (the “Inducement Grants”) on April 6, 2026 (the “Grant Date”). The Inducem...